Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Prelude Therapeutics ( (PRLD) ).
Prelude Therapeutics has appointed Bryant D. Lim as the permanent Chief Financial Officer, effective February 3, 2025, while he continues his roles as Chief Legal Officer and Corporate Secretary. This decision follows his interim CFO position, and his employment agreement includes a base salary, bonus eligibility, stock options, and benefits contingent upon his continued service and compliance with the agreement.
More about Prelude Therapeutics
YTD Price Performance: -11.20%
Average Trading Volume: 452,252
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $61.09M
Find detailed analytics on PRLD stock on TipRanks’ Stock Analysis page.